JHK-02-108-2
JHK-02-108-2 is a PROTAC degrader targeting CDK6, with an EC50 of 0.22 μM and a Kd of 1.9 μM. JHK-02-108-2 selectively promotes CRBN-dependent ubiquitination and proteasomal degradation of CDK6. JHK-02-108-2 induces sustained cell cycle arrest at the G1 phase. JHK-02-108-2 reduces the phosphorylation level of retinoblastoma protein. JHK-02-108-2 can be used in research related to acute myeloid leukemia and glioblastoma.
(Pink: CDK6 ligand (HY-184911); Blue: Cereblon E3 ligase ligand; Black: linker (HY-W259900)).
For research use only. We do not sell to patients.
- Formula: C49H56F4N10O8
- Molecular Weight:989.02
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK6 0.22 μM (EC50) |
CDK6 1.9 μM (Kd) |
In Vitro
JHK-02-108-2 (1 μM; 5 h) selectively degrades CDK6 in MOLT-4 cells, as measured by global proteomics[1].
JHK-02-108-2 (0.01-50 μM; 6 h, 24 h) induces dose-dependent, selective, and sustained degradation of CDK6 (with no hook effect) in MOLT-4 cells[1].
JHK-02-108-2 (0.001-100 μM) induces dose-dependent degradation of CDK6 in K562-Cas9 reporter cells, which is blocked by palbociclib (a CDK6 ATP-competitive inhibitor) but not by regorafenib[1].
JHK-02-108-2 (0.0001-100 μM) does not inhibit CDK6/cyclin D1 kinase activity at concentrations up to 100 μM in an in vitro kinase assay[1].
JHK-02-108-2 (0.0001-100 μM) binds purified CDK6 protein with a Kd of 1900 nM in an in vitro binding assay[1].
JHK-02-108-2 (200 nM; 7-60 sec) induces CRBN-dependent ubiquitination of purified CDK6 protein in an in vitro ubiquitination assay, with detectable activity within 7 sec of incubation[1].
JHK-02-108-2 (0.001-100 μM) induces ternary complex formation between purified CRBN-DDB1 and CDK6 proteins with an EC50 of 0.22 μM in a TR-FRET assay, with a hook effect at concentrations above 1 μM[1].
JHK-02-108-2 (0.01-10 μM; 72 h, 1 μM; 24 h) inhibits growth (IC50 = 0.64 μM), induces G1 cell cycle arrest, and degrades CDK6 (DC50 = 11 nM) in BT145 GBM cells, with near-complete CDK6 loss after 24 h treatment with 1 μM[1].
JHK-02-108-2 (0.001-10 μM; 72 h) reduces cell viability and induces G1 arrest in FLT3WT and FLT3ITD AML cell lines, with greater selectivity over its negative control in FLT3WT lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MOLT-4 cells
-
Concentration:0.01-50 μM (6 h incubation); 0.01-10 μM (24 h incubation)
-
Incubation Time:6 h; 24 h
-
Result:Induced dose-dependent degradation of CDK6 after 6 h, with no degradation of CDK4 and no observable hook effect at concentrations up to 50 μM.
Induced more prolonged CDK6 degradation compared to the type I CDK6 degrader BSJ-03-123 after 24 h, with no rebound in CDK6 protein levels at lower concentrations.
-
Cell Line:BT145 glioblastoma (GBM) cells (CDKN2A loss)
-
Concentration:0.01-10 μM (72 h incubation for growth and cell cycle analysis); 1 μM (24 h incubation for immunofluorescence)
-
Incubation Time:72 h (growth and cell cycle analysis); 24 h (immunofluorescence)
-
Result:Inhibited BT145 cell growth with an IC50 of 0.64 μM.
Induced dose-dependent G1 cell cycle arrest.
Degraded CDK6 with a DC50 of 11 nM.
Confirmed near-complete loss of CDK6 signal after 24 h treatment with 1 μM via immunofluorescence.
-
Cell Line:FLT3-WT (U937, NOMO1, OCIAML2) and FLT3-ITD (MV4-11, MOLM13) acute myeloid leukemia (AML) cell lines
-
Concentration:0.001 μM; 0.01 μM; 0.1 μM; 1 μM; 10 μM
-
Incubation Time:72 h
-
Result:Reduced cell viability in all tested AML cell lines, with 2.5-3.9-fold greater activity than JHK-02-137 in FLT3-WT lines.
Showed stronger G1 arrest and antiproliferative effects in FLT3-ITD lines, though separation from JHK-02-137 was less pronounced.
Chemical Information
-
Molecular Weight 989.02
-
Formula C49H56F4N10O8
-
SMILES
O=C(CCC1N2C(N(C)C3=C2C=CC(OCC(NCCCCCCCCN4CCN(CC5=C(C(F)(F)F)C=C(NC(NC6=C(F)C=C(OC7=CC(C(NC)=O)=NC=C7)C=C6)=O)C=C5)CC4)=O)=C3)=O)NC1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)